Ravi Guttikonda1, Brian R Herts2, Frank Dong1, Mark E Baker3, Kathleen B Fenner4, Brad Pohlman4. 1. Imaging Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, United States. 2. Imaging Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, United States; Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, United States. Electronic address: hertsb@ccf.org. 3. Imaging Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, United States; Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, United States. 4. Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, United States.
Abstract
INTRODUCTION: The purpose of this study was to estimate total effective dose and cancer risk related to treatment monitoring and surveillance computed tomography (CT) scans in a cohort of patients diagnosed with lymphoma. METHODS: 76 patients with head, neck, chest, abdomen or pelvis CT and whole-body positron emission tomography (PET)/CT were identified from an institutional lymphoma database; this included 54 (71%) patients with non-Hodgkin and 22 (29%) patients with classical Hodgkin lymphoma. Average treatment and surveillance periods were 8 months (range, 3-14 mo) and 23 months (range, 1-40 mo), respectively. Radiation exposure was estimated from the dose-length product (DLP) for CT scans and milli-Curies and DLP for PET/CT scans. Cancer risk was estimated using the Biological Effects of Ionizing Radiation model. RESULTS: During their treatment period, 45 patients had 161 CT exams and 39 patients had 73 PET/CT exams. Mean effective dose was 39.3 mSv (range, 7.1-100 mSv). During the surveillance period, 60 patients had 378 CT exams and 25 patients had 39 PET/CT exams. Mean effective dose was 53.2 mSv (range, 2.6-154 mSv). Seventeen of 76 (22.4%) patients had total cumulative doses greater than 100 mSv. The mean increase in estimated cancer risk was 0.40%; the greatest estimated risk to any one patient was 1.19%. CONCLUSION: Mean total effective dose and mean estimated cancer risk were low in patients with lymphoma undergoing serial imaging, suggesting that theoretical risks of radiation-induced cancer need not be a major consideration in radiologic follow-up.
INTRODUCTION: The purpose of this study was to estimate total effective dose and cancer risk related to treatment monitoring and surveillance computed tomography (CT) scans in a cohort of patients diagnosed with lymphoma. METHODS: 76 patients with head, neck, chest, abdomen or pelvis CT and whole-body positron emission tomography (PET)/CT were identified from an institutional lymphoma database; this included 54 (71%) patients with non-Hodgkin and 22 (29%) patients with classical Hodgkin lymphoma. Average treatment and surveillance periods were 8 months (range, 3-14 mo) and 23 months (range, 1-40 mo), respectively. Radiation exposure was estimated from the dose-length product (DLP) for CT scans and milli-Curies and DLP for PET/CT scans. Cancer risk was estimated using the Biological Effects of Ionizing Radiation model. RESULTS: During their treatment period, 45 patients had 161 CT exams and 39 patients had 73 PET/CT exams. Mean effective dose was 39.3 mSv (range, 7.1-100 mSv). During the surveillance period, 60 patients had 378 CT exams and 25 patients had 39 PET/CT exams. Mean effective dose was 53.2 mSv (range, 2.6-154 mSv). Seventeen of 76 (22.4%) patients had total cumulative doses greater than 100 mSv. The mean increase in estimated cancer risk was 0.40%; the greatest estimated risk to any one patient was 1.19%. CONCLUSION: Mean total effective dose and mean estimated cancer risk were low in patients with lymphoma undergoing serial imaging, suggesting that theoretical risks of radiation-induced cancer need not be a major consideration in radiologic follow-up.
Authors: M P Crowley; S B O'Neill; B Kevane; D C O'Neill; J A Eustace; M R Cahill; B Bird; M M Maher; K O'Regan; D O'Shea Journal: Clin Transl Oncol Date: 2015-08-26 Impact factor: 3.405
Authors: Jaime L Wiebel; Nazanene H Esfandiari; Maria Papaleontiou; Francis P Worden; Megan R Haymart Journal: Thyroid Date: 2015-08-03 Impact factor: 6.568
Authors: Neetha Gandikota; Sidonie Hartridge-Lambert; Jocelyn C Migliacci; Joachim Yahalom; Carol S Portlock; Heiko Schöder Journal: Cancer Date: 2015-03-04 Impact factor: 6.860